Fabrication of Electrospun Levodopa-Carbidopa Fixed-Dose Combinations  

作　　者：Haitham Bukhary Gareth R.Williams Mine Orlu 

机构地区：[1]UCL School of Pharmacy,University College London,29‑39 Brunswick Square,London WC1N 1AX,UK [2]Department of Pharmaceutics,College of Pharmacy,Umm Al-Qura University,Makkah 24381,Saudi Arabia

出　　处：《Advanced Fiber Materials》2020年第4期194-203,共10页先进纤维材料（英文）

摘　　要：Introduction Parkinson’s disease(PD)is a disabling disorder that signifi-cantly affects a patient’s quality of life[1].Treatments are available,but only 10%of PD patients fully adhere to their treatment regimens[2].Non-adherence is a serious problem linked to worsening symptoms and increased motor fluc-tuations[3-5].Levodopa(LD)remains the most effective treatment for PD[6].However,a single dosing treatment is only effective in the early phase of the disease.In the severe phase,4-5 years after diagnosis,the therapeutic window of dopamine becomes narrow,and due to its short half-life of between 0.7 and 1.4 h dosing of LD will be required every 2 h[7-9].One way to ameliorate this issue is to co-admin-ister LD with carbidopa(CD),which can increase LD’s oral bioavailability to 40-70%[10].

关 键 词：ELECTROSPINNING NANOFIBER Fixed-dose combination POLYPHARMACY 

分 类 号：R74[医药卫生—神经病学与精神病学]